Analysts Set Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) PT at $3.86

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) has received an average recommendation of “Moderate Buy” from the nine ratings firms that are presently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell rating, seven have given a buy rating and one has issued a strong buy rating on the company. The average 12-month target price among brokers that have covered the stock in the last year is $3.8571.

RVPH has been the subject of several analyst reports. Chardan Capital raised shares of Reviva Pharmaceuticals to a “strong-buy” rating in a report on Wednesday, November 19th. HC Wainwright lowered their price objective on Reviva Pharmaceuticals from $11.00 to $4.00 and set a “buy” rating on the stock in a research report on Monday, October 27th. Citigroup restated a “buy” rating on shares of Reviva Pharmaceuticals in a research report on Friday, August 15th. Roth Capital reaffirmed a “buy” rating and issued a $3.00 price target (down previously from $7.00) on shares of Reviva Pharmaceuticals in a report on Monday, August 18th. Finally, Maxim Group dropped their price target on Reviva Pharmaceuticals from $5.00 to $2.00 and set a “buy” rating for the company in a research report on Friday, August 15th.

Hedge Funds Weigh In On Reviva Pharmaceuticals

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. XTX Topco Ltd purchased a new stake in shares of Reviva Pharmaceuticals during the 2nd quarter valued at $31,000. Lido Advisors LLC bought a new position in Reviva Pharmaceuticals in the third quarter valued at $37,000. NewEdge Advisors LLC bought a new position in Reviva Pharmaceuticals in the first quarter valued at $58,000. Geode Capital Management LLC raised its position in Reviva Pharmaceuticals by 6.9% during the second quarter. Geode Capital Management LLC now owns 448,202 shares of the company’s stock valued at $171,000 after purchasing an additional 29,063 shares in the last quarter. Finally, Persistent Asset Partners Ltd lifted its stake in Reviva Pharmaceuticals by 300.0% during the second quarter. Persistent Asset Partners Ltd now owns 641,174 shares of the company’s stock worth $244,000 after purchasing an additional 480,864 shares during the last quarter. Hedge funds and other institutional investors own 63.18% of the company’s stock.

Reviva Pharmaceuticals Stock Up 4.2%

RVPH stock opened at $0.62 on Tuesday. The stock has a 50-day simple moving average of $0.56 and a two-hundred day simple moving average of $0.55. Reviva Pharmaceuticals has a twelve month low of $0.25 and a twelve month high of $4.28. The firm has a market capitalization of $70.89 million, a PE ratio of -1.34 and a beta of -0.02.

Reviva Pharmaceuticals (NASDAQ:RVPH) last announced its quarterly earnings results on Thursday, November 13th. The company reported ($0.06) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.05. On average, equities research analysts anticipate that Reviva Pharmaceuticals will post -0.97 EPS for the current fiscal year.

About Reviva Pharmaceuticals

Reviva Pharmaceuticals Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis.